Antifungal susceptibility testing of the mold phase was performed at the Fungal Testing Laboratory, University of Texas (San Antonio, TX, USA). The following MICs were obtained: amphotericin B, 0.125 µg/mL at 24 and 48 h; caspofungin, 0.5 µg/mL at 24 h and 2 µg/mL at 48 h; voriconazole 0.125 µg/mL at 24 and 48 h; and posaconazole, <0.03 µg/mL at 24 and 48 h.
A literature review of human Emmonsia infections is challenging because these organisms have undergone multiple taxonomic revisions (2) . Most reports of adiaspiromycosis base the diagnosis solely on the appearance of adiaspores in histopathologic specimens (5,6), and some published Emmonsia cases might have misidentified the causative organism (1) .
Disseminated Emmonsia infection appears to be a separate clinical entity from adiaspiromycosis (1 
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mmonsia is a genus of soil fungus that can cause adiaspiromycosis, a pulmonary disease common in wild animals, but rare in humans, as well as disseminated disease. When aerosolized spores are inhaled, they enlarge dramatically, from 2-4 μm to 40-500 μm in diameter. Because these swollen cells do not replicate, Emmons and Jellison termed them "adiaspores" (from the Greek a ["not"] + dia ["by"] + spora ["sowing"]. Emmonsia was first described by Chester W. Emmons, senior mycologist with the US Public Health Service, as Haplosporangium parvum in 1942. In 1958, it was reclassified into a separate genus and named in honor of Emmons. Recent phylogenetic analyses have concluded that fungi in this genus are polyphyletic, and proposed taxonomic changes may render the genus name obsolete.
Emmonsia [ĕ-monʹse-ə]
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